June 2026

Middle socioeconomic status (SES) elevates multimorbidity risk; healthy lifestyles mitigate this. Targeted interventions for middle-SES populations, especially middle-aged non-Hispanic White women, are crucial.

The problem is not that price transparency itself has failed, but rather that policy makers have focused their efforts on the wrong place.

Implementation of surgeon-led Musculoskeletal Quality Collaborative protocols reduced high-cost consumable utilization without compromising patient safety. Systemwide collaboratives can reduce high-cost consumable utilization while maintaining low infection rates.

Participants exposed critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure with preserved ejection fraction and charted a path forward.

Clinicians discussed the fragmented state of obesity care, emphasizing the need for coordinated models, earlier intervention, and improved access to effective therapies.

A multidisciplinary roundtable exposed deep inequities in vitiligo care—from payer misclassification to access barriers—while charting a more ambitious treatment future.

Clinicians gathered in Houston, Texas, to examine how newer drug options are reshaping cardiometabolic care and how integrated health systems can put evidence into practice.

Socioeconomic, racial, and institutional factors significantly affect treatment access and patient outcomes in Guillain-Barré syndrome, despite standardized care guidelines in the US.

Beneficiaries in socially vulnerable communities received higher-quality, more-efficient care under value-based care (at-risk Medicare Advantage) compared with those in fee-for-service Medicare payment arrangements.

The authors examined experiences with Pennsylvania’s implementation of opioid settlement funds, identifying 7 themes and highlighting opportunities to improve administration and ensure effective fund distribution.

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack competitive conditions. Learnings from transparency will shape future drug pricing reforms.

Using price transparency data to select high-value providers will require improving the quality of the data, presenting the data intuitively, and making it easier to act on the information.

Employers can use price transparency data to reconsider their choice of carriers or plans, negotiate prices with their carriers, and steer employees toward high-quality, reasonably priced providers.